论文部分内容阅读
目的探讨新海能注射液在辅助晚期胃肠道肿瘤患者化疗中的作用及临床意义。方法将104例晚期胃肠道肿瘤患者随机分为治疗组(53例)和对照组(51例)。治疗组采用新海能注射液联合FOLFOX4方案治疗;对照组为同期FOLFOX4方案联合10%葡萄糖注射液患者,对比两组在近期疗效、生活质量、免疫指标、毒副作用、血液生化指标等方面的不同。结果FOLFOX4联合新海能注射液治疗方案治疗晚期胃肠道肿瘤疗效确切,血液学毒性反应、胃肠反应、神经毒性以及脱发等副作用均显著低于单纯FOLFOX4方案治疗组,患者的生活质量明显改善,治疗耐受能力增强,机体免疫力提高。结论FOLFOX4化疗方案联合新海能注射液治疗晚期胃肠道肿瘤,能改善患者生活质量,降低化疗期间的毒副作用,提高免疫力,可使患者病情进展延缓。
Objective To investigate the role and clinical significance of Xinhaiine injection in the chemotherapy of patients with advanced gastrointestinal cancer. Methods 104 cases of advanced gastrointestinal cancer patients were randomly divided into treatment group (53 cases) and control group (51 cases). The treatment group was treated with Xinhaiine injection combined with FOLFOX4 regimen; the control group was treated with FOLFOX4 regimen combined with 10% glucose injection in the same period. The differences in short-term curative effect, quality of life, immune index, toxic and side effects and blood biochemical indexes were compared between the two groups. Results FOLFOX4 combined with Xinhaiine injection was effective in treating advanced gastrointestinal cancer. Hematological toxicity, gastrointestinal reaction, neurotoxicity and hair loss were significantly lower than those treated with FOLFOX4 alone. The quality of life of the patients was significantly improved, Treatment tolerance increased, the body’s immune system increased. Conclusion FOLFOX4 chemotherapy combined with Xinhaiine injection in the treatment of advanced gastrointestinal cancer can improve the quality of life of patients, reduce the side effects during chemotherapy, improve immunity and prolong the progression of patients.